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ABSTRACT
Introduction The effects of SARS- CoV-2 in pregnancy 
are not fully delineated. We will describe the incidence of 
COVID-19 in pregnancy at population level in Scotland, 
in a prospective cohort study using linked data. We will 
determine associations between COVID-19 and adverse 
pregnancy, neonatal and maternal outcomes and the 
proportion of confirmed cases of SARS- CoV-2 infection in 
neonates associated with maternal COVID-19.
Methods and analysis Prospective cohort study using 
national linked data sets. We will include all women in 
Scotland, UK, who were pregnant on or became pregnant 
after, 1 March 2020 (the date of the first confirmed case 
of SARS- CoV-2 infection in Scotland) and all births in 
Scotland from 1 March 2020 onwards. Individual- level 
data will be extracted from data sets containing details 
of all livebirths, stillbirth, terminations of pregnancy and 
miscarriages and ectopic pregnancies treated in hospital 
or attending general practice. Records will be linked 
within the Early Pandemic Evaluation and Enhanced 
Surveillance of COVID-19 (EAVE II) platform, which includes 
primary care records, virology and serology results and 
details of COVID-19 Community Hubs and Assessment 
Centre contacts and deaths. We will perform analyses 
using definitions for confirmed, probable and possible 
COVID-19 and report serology results (where available). 
Outcomes will include congenital anomaly, miscarriage, 
stillbirth, termination of pregnancy, preterm birth, neonatal 
infection, severe maternal disease and maternal deaths. 
We will perform descriptive analyses and appropriate 
modelling, adjusting for demographic and pregnancy 
characteristics and the presence of comorbidities. The 
cohort will provide a platform for future studies of the 
effectiveness and safety of therapeutic interventions and 
immunisations for COVID-19 and their effects on childhood 
and developmental outcomes.
Ethics and dissemination COVID-19 in Pregnancy in 
Scotland is a substudy of EAVE II(, which has approval 
from the National Research Ethics Service Committee. 
Findings will be reported to Scottish Government, 
Public Health Scotland and published in peer- reviewed 
journals.
INTRODUCTION
The effects of novel SARS- CoV-2 in preg-
nancy are yet to be fully delineated.1 Pregnant 
women are at greater risk of complications 
and severe disease from infection with other 
coronaviruses including SARS and middle 
eastern respiratory syndrome.2 3 Pregnant 
women were thus identified as a potential 
vulnerable group in some countries and 
advised to take additional precautions as the 
COVID-19 pandemic unfolded.2–4
To inform public health policy, it is crucial 
to determine the effects of SARS- CoV-2 infec-
tion on maternal, pregnancy and neonatal 
health. SARS- CoV-2 transmission from 
mother to baby (antenatally or intrapartum) 
appears to be possible,5 but the proportion of 
pregnancies affected and the clinical signifi-
cance are uncertain. Potential effects of the 
virus on miscarriage, congenital anomalies, 
fetal growth, timing of delivery and stillbirth 
are unknown. We know from other viral 
Strengths and limitations of this study
 ► We will interrogate Scottish national data at the pop-
ulation level to provide information on the incidence 
of, and outcomes following, COVID-19 outcomes in 
pregnant women.
 ► We are expanding an existing national pandemic 
reporting platform (Early Pandemic Evaluation and 
Enhanced Surveillance of COVID-19 EAVE II) to in-
clude assessment of all pregnancy outcomes. EAVE 
II uses deidentified individual patient- level data for 
almost the entire population of Scotland from gen-
eral practices, hospitals, death registry, virology 
(reverse transcriptase PCR) and serology tests to 
investigate the epidemiology of COVID-19.
 ► This is an observational study and residual con-
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infections in pregnancy that infections with mild maternal 
symptomatology can have substantial impacts on the 
developing fetus (eg, cytomegalovirus, parvovirus, zika 
virus),6 although mechanisms of placental transmission 
of virus vary.7 The canonical receptors for SARS- CoV-2 
(the angiotensin- converting enzyme 2 receptor and the 
serine protease TMPRSS2) are not coexpressed in the 
placenta, making placental infection unlikely.8 9 Neverthe-
less, case reports have shown evidence suggestive of viral 
infection of the placenta, in association with pregnancy 
complications such as pre- eclampsia and abruption10 
and second trimester miscarriage.11 Reports that include 
neonatal test results for SARS- CoV-2 show positive cases 
only in a minority of babies, with significant respiratory 
disease being rare in neonates.12 However, some babies 
born to mothers who had COVID-19 have increased 
concentrations of both immunoglobulin IgM and IgG 
for SARS- CoV-2.13 14 As IgM cannot cross the placenta, 
neonatal circulating SARS- CoV-2 IgM indicates vertical 
transmission of virus, although all the infants in reports 
so far have been asymptomatic and tested negative for 
SARS- CoV-2 viral RNA at birth.13 14 There are also plau-
sible links between SARS- CoV-2 and pregnancy compli-
cations such as preterm birth, which may be mediated 
either as a manifestation of COVID-19 disease itself or 
indirectly through increased stress due to the pandemic 
and containment measures or through altered physician 
threshold for iatrogenic preterm delivery in women with 
infection.1
Understanding the effects of COVD-19 at different 
stages in pregnancy and perinatally will help inform policy 
on shielding strategies and advice to pregnant women 
and those considering pregnancy. It is also essential to 
inform immunisation strategies when vaccines are avail-
able. For example, immunisation in early pregnancy may 
help protect against maternal infection during pregnancy 
and reduce complications; but immunisation in later 
pregnancy may be preferential to provide passive immu-
nisation to babies if neonatal infection is the predomi-
nant concern.
There are a number of surveillance studies gathering 
data on pregnant women with COVID-19 currently 
underway in the UK, summarised in table 1.
Collectively, these surveillance studies can provide 
detailed characterisation of selected groups of preg-
nant women (and neonates) affected by COVID-19. 
The study outlined in this protocol will complement 
these existing studies by providing population- based 
information (for the whole of Scotland) on the risks of, 
and outcomes following, COVID-19 at any stage of preg-
nancy for women in the community and/or admitted to 
hospital.
The primary objectives of the COVID-19 in Pregnancy 
in Scotland study are to:
a. Describe the incidence of SARS- CoV-2 infection and 
COVID-19, in the pregnant population.
b. Determine associations between COVID-19 and ad-
verse maternal, pregnancy and neonatal outcomes.
c. Determine the proportion of neonates with con-
firmed SARS- CoV-2 infections that are associated with 
COVID-19 in the baby’s mother
Secondary objectives are to:
a. Assess the proportion of COVID-19 cases in pregnant 
women and neonates who are included in relevant oth-
er enhanced surveillance studies (eg, British Paediatric 
Surveillance Unit (BPSU), Clinical Characterisation 
Protocol Tier 0 study (CO- CIN))15–17.
b. Provide a platform to assess the safety and effectiveness 
of any new or existing prophylactic or therapeutic in-
terventions (eg, new or repurposed therapies, vaccines, 
antimicrobials) in pregnant women and their babies.
c. Enable evaluation of the longer term sequelae of ma-
ternal SARS- CoV-2 and therapeutic interventions to 
mitigate SARS- CoV-2 in pregnancy and in children.
This COVID-19 in Pregnancy in Scotland (COPS) 
study is a substudy of the Early Pandemic Evaluation and 
Enhanced Surveillance of COVID-19 (EAVE II).18–20 EAVE 
II is a national, real- time, data platform to identify the 
population groups most at risk from SARS- CoV-2 infec-
tion and COVID-19 disease and mortality, linking Scot-
tish general practice (GP) records (5.4 million registered 
patients) with secondary care and laboratory datasets.18 
Pregnancy will be assessed as one of these at- risk groups. 
Within this COPS study protocol, we specify in detail the 
national data sets that will be incorporated within the 
EAVE II platform to enable pregnant women (and asso-
ciated pregnancy start and end dates) to be reliably iden-
tified. We also specify in detail the maternal, pregnancy 
and neonatal outcomes following maternal COVID-19 
that will be examined.
METHODS
Patient and public involvement
Parents and pregnant women have not been involved in 
design of this protocol. However, we will work in partner-
ship with a patient and public involvement group set up 
for the EAVE II study regarding interpretation of results, 
presentation and dissemination of findings. We also have 
close links with Tommy’s charity who will codevelop 
dissemination plans and help ensure that findings reach 
relevant stakeholders.
Study design and population
This is a prospective cohort study using national mater-
nity, community, hospital and laboratory- linked data sets, 
in Scotland, UK. We will include all women in Scotland 
who were pregnant on or became pregnant after 1 March 
2020 (the date of the first confirmed case of SARS- CoV-2 
infection in Scotland)21 and all live- born babies born 
in Scotland from 1 March 2020 onwards. The end date 
for the study will be determined by the future develop-
ment, and, in particular, suppression of the pandemic in 
Scotland.
Women in the cohort with the earliest dates of concep-
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end of their pregnancy. Women with more recent dates of 
conception will have been at risk for longer, up to women 
with date of conception from 1 March 2020 onwards, who 
will be at risk from conception onwards (until viral trans-
mission is completely suppressed).
We aim to use a dynamic cohort of the entire pregnant 
population; therefore, selection bias is not anticipated 
and the data set will be fully generalisable to Scotland 
(with extensive generalisability to other high- income 
nations).
Databases
Individual- level data will be extracted from the datasets 
listed below. Records relating to the same individual will 
be linked deterministically using the Community Health 
Index (CHI) number.22 The CHI number is a unique 
identifier provided by National Health Service (NHS) 
Scotland for each resident registered with a GP. Public 
Health Scotland (PHS) routinely adds both maternal and 
baby CHI numbers to live birth registration records: these 
‘spine’ records will be used to facilitate intergenerational 
linkage of records relating to mothers and their babies.
An overall scheme for the planned linkage is provided 
in figure 1. Unless otherwise specified, included data sets 
are held by PHS and PHS is the data controller.
Data sets to identify pregnant women in the general population 
and associated pregnancy start and end dates and pregnancy and 
neonatal outcomes
1. Antenatal booking records: this is a new national 
data return developed as part of the response to the 
COVID-19 pandemic providing information on all 
women booking for antenatal care with NHS maternity 
services throughout Scotland. It will be used for iden-
tification of women with ongoing pregnancies in near 
real time. All other records identify end of pregnancy 
Table 1 UK surveillance studies on COVID-19 in pregnant women and their babies
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events, thus, there is a time- lag before records are gen-
erated. More than 99% of births in Scotland book for 
antenatal care with NHS maternity services.23
2. Abortion Act Scotland (AAS) records: these are stat-
utory notifications of termination of pregnancy and 
will be used to identify all terminations of pregnan-
cy, including terminations of pregnancy indicated by 
congenital anomaly.24
3. National Records of Scotland (NRS) statutory still-
birth registrations: Scottish legislation requires all 
stillbirths at 24 weeks gestation or more to be regis-
tered with NRS.25
4. NRS statutory live birth registrations: Scottish legis-
lation requires all live births at any gestation to be 
registered with NRS.26
5. NHS Scottish health board live births: A new national 
data return developed as part of the response to the 
COVID-19 pandemic (specifically to mitigate unavail-
ability of NRS statutory live birth registration records 
when registration processes were suspended) provid-
ing information on all live births notified by materni-
ty services to NHS Board child health administrative 
departments.
6. GP data: data from all patients registered in GPs 
are included in the EAVE II platform.18 In COPS, 
these records will be used for identification of wom-
en with early miscarriage or ectopic pregnancy not 
managed in hospitals and potential confounding 
comorbidities.
7. Scottish Morbidity Record (SMR) 01: the SMR01 da-
tabase includes all general day case and in- patient 
admissions in Scotland.27 Admissions to neonatal, 
maternity and mental healthcare are excluded from 
SMR01 as they are covered by other specialist data 
sets. SMR01 records are included in the EAVE II 
platform, and COPS will be used for identification 
of women with early miscarriage or ectopic pregnan-
cy managed in hospitals and potential confounding 
comorbidities.
8. SMR 02: the SMR02 database includes all day case 
and in- patient admissions to maternity specialities in 
Scotland.27 It will be used for identification of later 
miscarriage, stillbirth and live births managed in ma-
ternity units (≥98% of births in Scotland) and some 
home births (≤2% of births in Scotland).23
9. Scottish Birth Record (SBR): the SBR records ba-
sic demographic data on all births in Scotland and 
additional clinical information and diagnostic and 
operational procedure codes on babies admitted to 
neonatal care.28 It will be used to identify neonates 
admitted to neonatal care.
10. Scottish Intensive Care Society Audit Group records: 
this is a national database of patients admitted to 
adult general critical care units in Scotland detailing 
Figure 1 Overview of data linkage for the COPS study. AAS,Abortion Act Scotland; BPSU, British Paediatric Surveillance 
Unit; CO- CIN,Clinical Characterisation Protocol Tier 0 study; COPS, COVID-19 in Pregnancy in Scotland; ECOSS,Electronic 
Communication of Surveillance in Scotland; GP, generalpractice;HEPMA, Hospital Electronic Prescribing and Medicines 
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information on the management of critically ill or 
injured patients. All general intensive care units and 
combined ICU/high dependency units (HDUs) col-
lect data and more than 90% of general HDUs and a 
number of specialist ICU and HDUs also provide re-
cords.29 In COPS, these will be used to identify wom-
en admitted to critical care with COVID-19.
Data sets to identify women with confirmed SARS-CoV-2 infection 
or COVID-19
1. Electronic Communication of Surveillance in Scotland 
(ECOSS)30 and other viral reverse transcriptase PCR 
(RT- PCR) and serology results held separately by PHS 
are included on the EAVE II platform.18 In COPS, these 
will be used for identification of pregnant women and 
neonates with positive viral RT- PCR and serology and 
women with negative viral RT- PCR.
ECOSS is a database that holds surveillance data on 
various microorganisms (eg, influenza virus, coronavi-
rus) and infections reported from NHS diagnostic and 
reference laboratories.30 Data on laboratory results for 
all SARS- CoV-2 RT- PCR tests carried out in Scotland 
are being collated by ECOSS and can be linked to oth-
er data sources.30
In substudies, residual sera from routine antena-
tal booking blood tests and 28- week gestation blood 
group and red cell antibody screen samples will be 
tested for SARS- CoV-2 antibodies. Residual sera from 
other blood tests conducted as part of routine (not 
COVID-19 related) primary and secondary care, and 
blood donation, are also being tested for SARS- CoV-2 
antibodies as part of the surveillance of the pandemic 
in Scotland, and any results relating to pregnant wom-
en will also be incorporated.31Results from these sub-
studies will be linked to pregnancy records and used to 
determine exposure to SARS- CoV-2 by the presence of 
antibodies.18
2. GP consultations, GP out of hours attendances, NHS24 
calls, COVID-19 phone assessment hub calls and 
COVID-19 clinical assessment centre attendances are 
linked on the EAVE II platform.18 We will extract data 
on pregnant women with possible COVID-19 from 
GP records and a network of COVID-19 Communi-
ty Hubs and Assessment Centres established by NHS 
Health Boards across Scotland. These provide a direct 
and rapid route for people with COVID-19 symptoms 
that have worsened or not improved after a week to 
seek advice and primary care. The pathway for man-
agement of patients in the community with symptoms 
suggestive of COVID-19 has evolved as the pandem-
ic has progressed. In early March 2020, patients with 
symptoms were advised to phone their GP in hours or 
NHS 24 out of hours for advice. Patients requiring face 
to face assessment were then seen in GP surgeries or 
GP out of hour centres. On 17 March 2020, the Scot-
tish Government published details of a new national 
patient pathway, whereby all patients with symptoms 
(in or out of hours) were encouraged call NHS 24 as 
the initial point of contact.32 Patients thought likely to 
have COVID-19 were then passed to a new, dedicated 
NHS24 COVID-19 phone assessment hub. Those re-
quiring face- to- face assessment in general were then 
seen in (or visited at home by staff from) an NHS24 
COVID-19 clinical assessment centre, although preg-
nant women could alternatively be directed to their 
maternity service triage base.32
3. Unscheduled Care Datamart: This links data from NHS 
24, Scottish Ambulance Service, Out of Hours Prima-
ry Care, Emergency Department, Acute and Mental 
Health admissions and Deaths to show a Continuous 
Unscheduled Care Pathway. Data are included in the 
EAVE II platform.18 In COPS, we will use Scottish Am-
bulance Service incident and Accident and Emergency 
(A&E) attendance records for identification of women 
with possible COVID-19.33
4. NRS statutory death registrations will be used for iden-
tification of any women with COVID-19 recorded as 
cause of death.34
5. SMR01, SMR02 and NRS stillbirths will be used to 
identify women with COVID-19 recorded as cause of 
admission/stillbirth.25 27
Data sets recording treatments, vaccination, shielding status and 
inclusion in other studies
1. Prescribing information system includes information 
on all prescribed medications that are dispensed in 
the community in Scotland.35 Lookback records are in-
cluded in the EAVE II platform18 and used to provide 
information on the presence of comorbidities.COPS 
records will also be used to provide information on 
COVID-19 treatments given.
2. Scottish Hospital Electronic Prescribing and Medi-
cines Administration systems are currently available 
within four Scottish hospitals, and data from these are 
linked in the EAVE II platform18 to provide data on 
medications for COVID-19 administered in hospitals.36
3. GP consultation records included on the EAVE II plat-
form18 will be used to extract information on vaccina-
tions for SARS- CoV-2 and other viruses.
4. We will identify pregnant women and neonates with 
COVID-19 in existing enhanced surveillance studies 
using minimal ‘flag’ variables from the BPSU and CO- 
CIN studies15–17 as well as other trials who can provide 
this data.
Exposure and outcome definitions
Pregnancy, start and end dates and pregnancy outcomes
A pregnancy will be defined by presence of a record 
pertaining to a pregnancy. As well as identifying 
completed pregnancies, through a record of any preg-
nancy outcome, we will be able to identify ongoing preg-
nancies at population level, through inclusion of records 
from women booked for antenatal care.
The following definitions will be used for pregnancy 
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relevant records are described in detail in online supple-
mental material.
1. Ectopic pregnancy: this will include any early pregnan-
cy loss where the pregnancy is implanted outwith the 
uterus
2. Spontaneous pregnancy losses: these will be defined as 
miscarriage at less than 20 weeks gestation, late fetal 
losses at 20–23 weeks if there are no signs of life; and 
stillbirth if birth occurs at 24 weeks’ gestation or more 
and there are no signs of life. If numbers allow, the mis-
carriages will be further split into the more clinically 
meaningful outcome categories of miscarriage at less 
than 14 weeks gestation and 14 weeks gestation and 
beyond.
3. Termination of pregnancy: these will be subclassified 
by the grounds for termination of pregnancy of the 
Abortion Act 1967.37
4. Live birth: the birth of a baby at any gestation with 
signs of life. No lower gestational limit will be used al-
though in practice around 22 weeks gestation would 
be considered the lower limit at which live- born babies 
may survive
Pregnancy start date will be taken as the date of concep-
tion. In pregnancies that have ended date of conception 
will be imputed from
‘date of conception=pregnancy end date —(the number 
of weeks of gestation at pregnancy end+2 weeks)’.
In ongoing pregnancies that have booked with mater-
nity services and have a documented estimated date of 
delivery (EDD), date of conception will be imputed from
‘date of conception=date of antenatal booking—(gesta-
tion at booking+2 week)’.
In ongoing pregnancies without a documented EDD, 
date of conception will be imputed from
‘date of conception=date of last menstrual period+2 
weeks’.
It is standard care for women who book with maternity 
services in Scotland have a first trimester ultrasound scan 
(usually 11–13+6 weeks gestation) to determine EDD, 
from which gestation is calculated. Booking takes place 
around 10 weeks gestation.
SARS-CoV-2 infection and COVID-19
We will use the following definitions for COVID-19.
 ► Confirmed COVID-19 in pregnancy will be defined as 
positive viral PCR for SARS- CoV-2 on a test.
 ► Probable COVID-19 will be defined as COVID-19 
recorded on a hospital admission, stillbirth or a 
maternal death record (using International Classifica-
tion of Diseases (ICD) 10 codes U07.1, U07.2, B34.2, 
B97.2).
 ► Possible COVID-19 will be defined as meeting one or 
more of the following criteria:
 – GP consultation or GP out of hours attendance 
coded as possible COVID-19.
 – NHS24 call coded as possible COVID-19.
 – Patient triaged to NHS24 COVID-19 phone assess-
ment hub or clinical assessment centre.
 – Scottish Ambulance Service call for possible 
COVID-19.
 – A&E attendance coded as possible COVID-19.
 – Negative SARS- CoV-2 viral PCR test when the test 
was taken for clinical indications (ie, excluding 
tests taken for routine testing of asymptomatic 
individuals).
The above definitions are hierarchical, for example, a 
positive SARS- CoV-2 nucleic acid test assigns a woman to 
the confirmed COVID-19 group, regardless of the pres-
ence of other records.
We will use the indication for SARS- CoV-2 nucleic acid 
test, which is recorded in ECOSS records, to distinguish 
between tests taken for clinical indications and routine 
testing of asymptomatic individuals. If we can not distin-
guish between these groups, we will exclude women 
testing negative from both the ‘case’ and ‘control’ 
groups—and base our definition of possible case on 
presentation to various healthcare settings with relevant 
symptoms as described above.
SARS- CoV-2 infections during pregnancy will be iden-
tified if the event of interest (eg, SARS- CoV-2 nucleic 
acid test taken, admission, unscheduled care attendance) 
occurs between 14 days prior to the estimated date of 
conception (to include women who could be viraemic 
periconceptually) and the end of pregnancy.
We will seek to access serological data as these become 
available. We will report the proportion of women with 
circulating IgG and/or IgM for SARS- CoV-2 and may 
incorporate serology results in case definitions and/or 
use in additional analyses as data mature. The timing of 
exposure to/infection with SARS- CoV-2 is more difficult 
to ascertain from serology results than from the other 
indicators of (possible) infection listed above. Dates 
of serological testing; start and end of pregnancy and 
plausible start (and, if applicable, end) of transmission 
of SARS- CoV-2 in Scotland will be taken into account 
when identifying women with exposure before, during 
and after pregnancy. Seroconversion windows will also be 
considered for women with sequential serology results.
We have included hierarchical definitions of COVID-19 
to mitigate against potential biases that may result from 
(1) limitations of diagnostic strategy performance and 
(2) variation in availability of diagnostic tests. The defi-
nition of confirmed COVID-19 (women who test posi-
tive on PCR) may potentially bias results away from the 
null hypothesis (due to false- negative PCR results). The 
definition of possible COVID-19 may potentially bias 
results towards the null hypothesis (due to false- positive 
‘diagnoses’). We will test our hypotheses in this observa-
tional cohort across the range of assumptions allowed by 
hierarchical definitions. Other diagnostic and exposure 
categories may be added as the pandemic develops and 
diagnostic criteria change.
Fetal and neonatal outcomes
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1. Congenital anomaly (major structural anomaly as de-
fined by European network of population- based regis-
tries for the epidemiological surveillance of congenital 
anomalies (EUROCAT)38 diagnosed in any pregnancy 
terminated at any gestation due to anomaly; miscar-
riage or stillbirth at ≥20 weeks or live- born baby diag-
nosed at <28 days of age).
2. Preterm birth (<37 weeks) categorised as spontaneous 
or medically indicated (ie, following induction of la-
bour or elective caesarean section undertaken to miti-
gate clinical risk).
3. Small for gestational age (birthweight <10th centile by 
WHO- UK90 growth reference.39
4. Admission to neonatal care.
5. Neonatal SARS- CoV-2 infection (currently defined as 
positive viral RT- PCR test on sample taken from baby 
aged 0–27 days, definition may be expanded to include 
results of serology tests as evidence and testing options 
accumulate).
6. Neonatal mortality (death of a live born baby at <28 
days of age).
7. Extended perinatal mortality (stillbirth or neonatal 
mortality).
Maternal outcomes
We will collect data on the following maternal outcomes:
 ► COVID-19 disease requiring any hospital admission 
(defined as a patient admitted within 14 days of 
confirmed or probable COVID-19 or with confirmed 
or probable COVID-19 during admission).
 ► Severe COVID-19 disease requiring critical care 
admission or resulting in death (defined as patient 
admitted to critical care or dying within 28 days of 
confirmed or probable COVID-19 or with confirmed 
or probable COVID-19 during hospital admission, 
regardless of recorded cause of death).
 ► Any maternal death (defined as the death of a woman 
while pregnant or within 42 days of the termination of 
pregnancy, irrespective of the duration and site of the 
pregnancy, from any cause related to or aggravated by 
the pregnancy or its management but not from acci-
dental or incidental causes).
Population characteristics and confounding factors
A number of maternal and pregnancy characteristics will 
be collected that could be potential confounders or effect 
modifiers.
1. Demographics including age band and socioeconom-
ic status determined by the Scottish Index of Multiple 
Deprivation (SIMD) classification of material depri-
vation.40 SIMD quintiles 1–5 refer to the small geo-
graphical areas (data zones) each containing 20% of 
the Scottish population, with quintile 1 indicating the 
most deprived areas. The SIMD is a combination of 
38 indicators of the following seven domains: income, 
employment, health, education, housing, geographi-
cal access to services and crime. We will also include 
urban/rural status of maternal residence based on the 
urban/rural eightfold classification,41 where 1 is as-
signed to large urban areas and 8 is assigned to remote 
rural areas. We recognise ethnicity to be a complex in-
dicator variable related to sociodemographic factors, 
health systems use, pregnancy and health outcomes 
and genetics. We will explore the possibility of includ-
ing self- reported maternal ethnicity although missing 
data may preclude this.
2. Clinical at- risk groups of individuals with certain un-
derlying medical conditions thought to increase risk 
of COVID- related complications. The following clin-
ical at- risk conditions are identified in the EAVE II 
platform18: (a) chronic respiratory disease, (b) chron-
ic heart disease, (c) chronic liver disease, (d) chronic 
kidney disease, (e) chronic liver disease, (f) chronic 
neurological disease, (g) diabetes, (h) conditions or 
medications causing impaired immune function, (i) 
asplenia or dysfunction of spleen and (j) body mass in-
dex (BMI). In addition, we will link pregnancy records 
with the shielded patient list included in the EAVE 
II platform (those with extremely high risk of severe 
manifestation of SARS- CoV-2 infection, and hence ad-
vised by Scottish Government to ‘shield’ during the 
pandemic). We will recategorise clinical risks for the 
pregnant population as (1) diabetes (type I; type II; 
other prepregnancy; gestational diabetes), (2) clinical-
ly vulnerable risk group (for whom seasonal influenza 
vaccination is recommended outwith pregnancy), (3) 
clinically extremely vulnerable risk group (those ad-
vised to ‘shield’ during the pandemic)42 and (4) no 
clinical at- risk condition. BMI, which can be associat-
ed with adverse pregnancy outcomes as well as COVID 
disease will be included separately, with prepregnancy 
BMI or BMI at antenatal booking categorised as under-
weight, normal, overweight, obese and severely obese 
according to WHO definitions.43 Other categorisation 
will be considered depending on number of pregnant 
women with these conditions and emergence of pat-
terns of risk for COVID-19 disease.
3. Smoking status in pregnancy will be presented into 
the following four categories: Current smoker, non- 
smoker, ex- smoker and not recorded. Smoking status 
will be taken from booking record and/or GP records.
4. Obstetric characteristics (SMR02) will include previous 
pregnancies, plurality (number of babies), drug and 
alcohol use, antenatal steroid administration, mode of 
birth or management of pregnancy loss.
5. Clustering of outcomes by the 14 different Maternal 
NHS Board areas of residence.
Statistical analysis
General approach
Baseline characteristics of all study participants will 
be described in relation to presence and absence of 
confirmed, probable or possible COVID-19 and outcomes 
of interest. Mean, median and proportions, together with 
a measure of dispersion, will be provided where appro-
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of interest based on the nature of each variable. Missing 
data will be provided for each variable. Two- tailed hypoth-
esis tests will be used for all study’s outcomes, with 95% 
CIs presented to show precision of estimates, and p values 
will be reported. All analyses will be carried out using the 
R statistical programming language. We do not propose 
to make any formal statistical adjustment for the multiple 
comparisons as the principal aim of the study is to estimate 
the effect of COVID-19 infection on pregnancy outcomes. 
The estimated effects and 95% CIs will be reported for 
the range of outcomes. However, a caveat will be clearly 
expressed regarding the dangers of overinterpreting 
these data, given the multiple outcomes used, particu-
larly if it transpires that conflicting results are obtained 
from the differing outcome measures. The approach 
to imputing estimated date of conception when gesta-
tion is missing on records indicating pregnancy status is 
detailed in online supplemental material 1. Missing data 
are otherwise not anticipated to be a substantial problem 
(and hence imputation techniques are not anticipated) 
but this will be confirmed once initial data extracts are 
available, and our approach to handling missing data will 
be confirmed prior to analysis.
Analyses will be updated monthly, providing results for 
sequential months, and also information on the cumu-
lative risk of COVID-19 as women progress through 
their pregnancies. Simple smoothing techniques such 
as rolling averages will be used to facilitate presentation 
and interpretation of findings. We will also present our 
results as proportions of COVID-19 infection, together 
with CIs based on the Wilson method. We will describe 
the temporal changes in the proportion using cumula-
tive risk models. Covariates such as the trimester of preg-
nancy, age of the mother and deprivation will also be 
included with a view to estimating the potential effects of 
these variables on the risk of COVID-19 infection
If/when numbers of cases allow, we will examine inci-
dence of COVID-19, and report outcomes, in subgroups 
including by maternal age band, SIMD deprivation quin-
tile, maternal NHS Board area of residence and maternal 
comorbidity status. We may assess whether findings are 
robust to more stringent or emerging definitions of 
confirmed and suspected infection, in sensitivity analyses. 
Other sensitivity and subgroup analyses may be indicated 
by initial findings. We will clearly state which analyses 
were prespecified and which were post hoc.
Incidence of SARS-CoV-2 and COVID-19 in the pregnant population
We will perform descriptive analysis of the number of 
cases over the total number of pregnancies, that is, how 
many pregnant women have had confirmed, probable or 
possible COVID-19/total number of pregnant women. 
Where timing of infection is known, we will describe inci-
dence of SARS- CoV-2 infection by trimester of exposure—
first trimester (0–13 weeks gestation), second trimester 
(14–27 weeks gestation), third trimester (≥28 weeks gesta-
tion)44; with denominators consisting of ongoing preg-
nancies in each trimester.
Associations between COVID-19 and adverse pregnancy, neonatal 
and maternal outcomes
Initially we will perform a descriptive analysis comparing 
pregnancy outcomes in women with and without (i) 
confirmed, (2) probable and (3) possible COVID-19. In 
order to create appropriate comparison groups, for each 
woman with COVID-19, we will identify 10 women without 
COVID-19, with an ongoing pregnancy matched on gesta-
tion of diagnosis, and additionally matched on maternal 
age and maternal deprivation level. We will explore the 
need to match additional parameters such as NHS Board.
Occurrence of the outcomes of interest will be 
compared in women with and without COVID-19 using 
simple descriptive statistics (eg, 95% CI for the differ-
ence in proportions, generated using methods that 
accommodate proportions close to zero) and visualised 
appropriately.
If/when sufficient cases of COVID-19 among pregnant 
women accrue, and the univariable comparisons described 
above suggest that outcomes differ between women with 
and without SARS-2- CoV or COVID-19, formal modelling 
will be undertaken to quantify the impact of infection on 
outcomes, adjusting appropriately for confounding. We 
will use direct acyclical graphs to identify which factors 
to adjust for to mitigate for confounding. Appropriate 
methods that accommodate the competing risk and time 
to event nature of pregnancy outcomes (example event 
history analysis and/or multistate modelling) will be used.
Association of SARS-CoV-2 in neonates with maternal COVID-19
We will use summary statistics to describe neonatal 
SARS- CoV-2 (currently defined as positive viral PCR for 
SARS- CoV-2 on sample taken from a baby aged 0–27 
days old) by presentation of COVID-19 in the mother in 
different time periods (apparent onset of maternal illness 
>14 days prior to birth; 14 days prior to birth—date of 
birth; day 1–13 following birth; day 14–27 following 
birth).
Proportion of pregnant women and neonates with COVID-19 
or SARS-CoV-2 that are included in relevant other enhanced 
surveillance studies (BPSU, CO-CIN)
We will use summary statistics to describe the number 
and proportion of cases included in the external surveil-
lance studies, and any factors associated with inclusion, 
for example, hospital admission status and NHS Board 
area of residence.
Creation of a platform to assess the safety and effectiveness of 
any new or existing prophylactic or therapeutic interventions and 
assessment of childhood outcomes after pregnancy exposure to 
COVID-19
We will use summary statistics to describe the treatments 
and prophylactic interventions used in pregnancy. We 
plan future linkage of data within COPS with child health 
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Sample size
There are approximately 50 000 live births in Scotland per 
year, 13 000 terminations of pregnancy, 5000 miscarriages 
managed in hospital and 200 stillbirths. The estimated 
number of women in the population who are pregnant at 
any one time is approximately 42 000.
We cannot influence the number of women with 
confirmed, probable or possible COVID-19 available 
for analysis, hence sample size calculations will not be 
performed. We will report the precision with which we 
are able to estimate any association between COVID-19 
and the outcomes of interest using CIs as appropriate. 
An approximate estimate of the expected number of 
confirmed COVID-19 cases in pregnant women from 
March to May 2020 is presented in table 2. It is likely that 
there will be further confirmed or probable cases in preg-
nant women identified through PCR testing processed 
through UK Government laboratories and clinical diag-
noses on discharge (or possibly stillbirth or maternal 
death) records. In addition, it is likely that there will be 
considerably more possible cases among pregnant women 
based on the range of data sources listed above.
ETHICS AND DISSEMINATION
COPS is a substudy of EAVE II, using unconsented data, 
which is covered by National Research Ethics Service 
Committee, South East Scotland 02 approval reference 
REC 12/SS/0201: SA 2 and Public Benefit and Privacy 
Panel approval reference 2021-0116. PHS and the Chief 
Medical Officer for Scotland are both (independent) 
data controllers for the national AAS database of termi-
nation of pregnancy notifications, thus the Chief Medical 
Officer has been informed of the intended use of AAS 
records for this study.
The results of monthly analyses summarising the inci-
dence of COVID-19 in pregnant women, and outcomes 
seen in women with COVID-19 and pregnant controls, 
will be reported through the PHS COVID-19- enhanced 
surveillance cell to the Scottish Government’s Chief 
Medical Officer’s COVID-19 Advisory Group. Any results 
of formal modelling of outcomes that is undertaken will 
be reported through the same route. Results reported 
through this route may be provided as management 
information (ie, without application of statistical disclo-
sure control restrictions) as appropriate.
Results will also be submitted for peer- reviewed 
academic publication and presented at international 
conferences. All results put into the public domain will 
be subjected to statistical disclosure control according to 
usual PHS processes. Meta- data produced in this study 
will also become available to Health Data Research UK 
Gateway. Strengthening the Reporting of Observational 
Studies in Epidemiology guidance45 and Reporting 
of studies Conducted using Observational Routinely- 
collected Data guidance46 will be used to guide trans-
parent reporting.
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Table 2 Estimated number of confirmed COVID-19 cases March to May 2020 in pregnant women in Scotland
Total number of individuals 
testing positive (PCR) for 
SARS- CoV-2 (NHS labs only)
Women aged 15–44 years testing 
positive (PCR) for SARS- CoV-2 
(NHS labs only)
Estimated number of pregnant 
women testing positive (PCR) for 
SARS- CoV-2 (NHS labs only)†
March 2020 ≈2000 ≈333* ≈17
April 2020 ≈9000 ≈1500* ≈75
May 2020 ≈4000 ≈667* ≈33
Total ≈15 000 ≈2500 ≈125
*Assuming the distribution over time for this age/sex group is the same as for all tests, as age/sex breakdown only available from published 
information50 for the total.
†Assuming that around 5% of the female population aged 15–44 is pregnant at any one time, and that incidence of COVID-19 is the same in 
pregnant and non- pregnant women.
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